Amyloid
15
4
5
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 15 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (15)
Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
Time-in-bed Restriction in Older Adults With Sleep Difficulties With and Without Risk for Alzheimer's Disease
[18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis
Pan-Amyloid PET/CT in Various Amyloid-Related Disease
Atrial Amyloid May Influence Outcomes in Patients Undergoing Surgical Aortic Valve Replacement
Beta Amyloid PET/CT in Various Aβ-Related Disease
Amyloidosis Incidence in High-Risk Cardiac Device Patients
Transdermal Trigeminal Electrical Neuromodulation on Mild Cognitive Impairment With Insomnia
18F-florbetaben PET-CT to Non-invasively Diagnose Cardiac AL Amyloidosis
Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease
Screening for Systemic Amyloidosis Via the Ligamentum Flavum
Detection of Amyloid Deposits in the Wrist by MRI With Mapping and High Resolution Sequences in Systemic Amyloidosis (AMYLOCARP)
Amyloid Proteins From Medullary Thyroid Cancer and Laryngeal Amyloidosis
Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD